Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q15/00—Anti-perspirants or body deodorants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/42—Amides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria

Definitions

• Tyrothricin for use in the treatment or prophylaxis of body odor and preparations therefor
• the present invention relates to the therapeutic or non-therapeutic use of tyrothricin for the treatment and / or prophylaxis of body odor in humans, preferably by local (topical), superficial application and / or preferably by application to the wound-free skin and / or mucosa.
• the invention further relates to a therapeutic, preferably pharmaceutical, or non-therapeutic, preferably cosmetic, composition containing tyrothricin and a keratolytic for the treatment and / or prophylaxis of body odor in humans.
• the invention relates to a kit containing tyrothricin and a keratolytic, as well as an article of footwear containing tyrothricin.
• Body odor in particular as an unpleasant body odor in humans, can primarily emanate from the skin surface, especially from the foot, the armpits or poorly ventilated skin folds ("intertriginous areas"), such as in the groin (inguinal) or below the breast area (submammary), or may also originate from mucous membranes (mucosa), such as the oral mucosa or the vaginal mucous membrane
• intertriginous areas such as in the groin (inguinal) or below the breast area (submammary
• mucous membranes mucous membranes
• unpleasant body odor of the aforementioned type or origin is usually caused and / or promoted and / or triggered by bacterial colonization and / or or certain bacterial metabolites.
• bromhidrosis refers to malodorous sweat and is a special form of hyperhidrosis in which the hyperhidrosis produces more Sweat constantly wets the horny layer of the skin and promotes the reproduction of the local germ flora there.
• hypohidrosis refers to malodorous sweat and is a special form of hyperhidrosis in which the hyperhidrosis produces more Sweat constantly wets the horny layer of the skin and promotes the reproduction of the local germ flora there.
• corneal keratin With the degradation of corneal keratin, degradation products, e.g. short-chain fatty acids and amines, which can be further metabolized by certain germs of said germ flora to various secondary products.
• Some of these germs appear to have a variety of metabolic pathways, some of which are exceptional in terms of seizure of certain metabolites: a peculiarity is, for example, the synthesis of mycothiol instead of glutathione observed in some microorganisms.
• volatile (especially short-chain) organic thiols seem to be produced as metabolites of some of the germs of said microbial flora.
• Volatile organic thiols often have a smell that is perceived by humans as being particularly unpleasant, in part unpleasant, and can therefore contribute significantly to an unpleasant body odor - especially in the area of the groin, armpits and feet, such as between the toes.
• apocrine secretion is generally the Process understood when secretory vesicles with surrounding apical cytoplasm are pinched off by a portion of the cell membrane from the glandular cell.
• Eccrine glands are glands that release their secretion, the secretion, to a free surface (e.g., the skin or digestive tract), which secretion occurs with no apparent microscopic cytoplasmic loss upon secretion (e.g., small sweat glands).
• Apocrine bromhidrosis refers to a pronounced secretion of sweat, predominantly through apocrine axillary sweat glands. Organic components of apocrine sweat are then decomposed by bacteria into unpleasant-smelling metabolites. Lack of hygiene favors the occurrence of apocrine bromhidrosis. It occurs predominantly at the sexually mature age.
• Ekkrine bromhidrosis refers to unpleasant odor due to secretion of eccrine sweat of various causes.
• the subculture of keratogenic eccrine bromhidrosis refers to a condition in which hyperhidrosis, leading to excessive hyperhidrosis, leads to a softening of the uppermost layer of skin (upper layer of the epidermis, stratum corneum), which is then decomposed by bacteria, with consequent odor formation.
• Keratogenic eccrine bromhidrosis occurs mainly in young and middle adulthood, and occasionally also in children, especially males, affecting mainly the areas of the soles of the feet (plantar), the palms of the hands ( palmar) as well as intertriginous areas.
• drying agents such as zinc oxide, soda, activated carbon and / or cedar wood
• sterilization of footwear by means of UV rays the wearing of natural wool socks, e.g. Merino wool socks and / or the use of certain nutritional supplements, e.g. Zinc.
• Tyrothricin (CAS RN: 1404-88-2, see also definition and description in the European Pharmacopoeia, eg according to entry 01/2005: 1662) is a mixture of various antibacterial and partly antifungal linear and cyclic polypeptides from the groups of gramicidines and tyrocidines ; In addition, other structurally related polypeptides are present in small quantities.
• Tyrothricin can be obtained from the fermentation broth of "Brevibacillus brevis Dubos "It is assigned to the polypeptide antibiotics, which also include actinomycin, bacitracin and the polymyxins.Through its antibacterial action, tyrothricin irreversibly damages the cell membrane of various microorganisms, resembling the antimicrobial peptides (also referred to as” host defense peptides "), as they are known from eukaryotes, z. Defensin and cathelicidin. Despite the decades-long use of tyrothricin, so far no resistance developments have become known as with other antibiotics.
• Tyrothricin is already used as a locally effective antibiotic in the form of throat pills for throat inflammation and pain with difficulty swallowing, in throat and laryngeal inflammation and in inflammation of the oral mucosa and gums.
• tyrothricin for the alleviating treatment of small-surface, superficial, little-weeping wounds of the skin with bacterial superinfection such. As cracking, scratching or abrasions.
• tyrothricin can be found e.g. in C. Lang et al. in Pharmacy ZI (2016) 299-305.
• Document DE 2316597 describes a dermatological preparation which enables an increased penetration of various pharmacologically active substances, including tyrothricin as an antimicrobial agent, for example for the superficial treatment of burns, into and through the tissue or the skin.
• the preparation described contains sugar esters or ethers in combination with a sulfoxide or a phosphine oxide.
• the document DE 36 04 865 A1 describes a skin cosmetic which i.a. Contains tyrothricin and is suitable for the treatment of superinfective dermatoses.
• the document EP 0 355 536 A2 describes a flexible, hydrophilic gel film and a process for its production and use. Tyrothricin is cited as one of the application examples of buccal application forms of the gel film.
• Another object of the invention was to provide a therapeutic or non-therapeutic, preferably cosmetic, composition suitable for use in the treatment and / or prophylaxis of body odor in humans, in particular body odor emanating from the skin surface.
• a specific further object of the invention was also to provide such aforementioned therapeutic or non-therapeutic, preferably cosmetic, compositions which have no or only a slight odor.
• a further object of the invention was to provide a kit which is suitable for use in the treatment and / or prophylaxis of body odor in humans, in particular body odor, which emanates from the skin surface.
• tyrothricin wherein the body odor is caused and / or promoted and / or triggered by bacterial colonization and / or bacterial metabolites and / or sweat formation and / or wherein the body odor with one or more of the aforementioned Apparitions goes along.
• a use according to the invention or a preferred use according to the invention is preferred, wherein the body odor emanates from the skin surface, preferably from the foot and / or the armpit and / or an intertriginous area and / or wherein the body odor emanates from a mucous membrane, preferably the oral mucosa and / or the vaginal mucosa.
• Intertriginous areas preferably comprise poorly ventilated areas of the skin surface in the groin (inguinal) and / or below the breast area (submammary), preferably below the female breast area, and / or spaces between the toes.
• the body odor emanates from the skin surface, preferably from the foot and / or the armpit and / or an intertriginous area, particularly preferably from the foot, including the intertriginous areas of the foot.
• tyrothricin is particularly preferred in case of excessive perspiration, preferably in the presence of excessive perspiration associated with an appearance which selected from the group consisting of hyperhidrosis, preferably primary focal hyperhidrosis, hyperhidrosis plantaris, axillary hyperhidrosis and / or hyperhidrosis pedis; Keratoma sulcatum (also referred to as "plantar pitting” or “pitted keratolysis", supra) and bromhidrosis, preferably apocrine bromhidrosis, eccrine bromhidrosis, and / or keratogenic eccrine bromhidrosis; and mixed forms of the aforementioned appearances.
• hyperhidrosis preferably primary focal hyperhidrosis, hyperhidrosis plantaris, axillary hyperhidrosis and / or hyperhidrosis pedis
• Keratoma sulcatum also referred to as "plantar pitting” or "pitted keratolysis", supra
• the application being local, superficial and / or the application being effected on the wound-free skin and / or on the wound-free mucous membrane, preferably on the wound-free skin.
• wound-free skin means that the skin is preferably uninjured and, in particular, does not have superficial wounds, such as, for example, lacerations, scrapes or abrasions Warts, keratinization and / or nail mycoses, on the other hand, fall within the scope of the present invention present invention not under the term "wound-free skin”.
• superficial wounds such as, for example, lacerations, scrapes or abrasions Warts, keratinization and / or nail mycoses
• a "local, superficial use or application” in the context of the present invention means that preferably the active ingredient tyrothricin is not percutaneously and / or non-systemically and / or transdermally, ie not absorbed through the skin into the organism, for example not in the Blood or lymphatic system acts, so not by resorption or absorption of tyrothricin through the skin and / or through the mucous membrane A local and / or superficial application or use of the invention, but the penetration of tyrothricin in the uppermost layer of skin or layer Include epidermis (stratum corneum), and possibly also in underlying skin layers.
• treatment period in the range of 1 to 7 days, in the range of 2 to 7 days as in the range of 3 to 7 days, and usually in the range of 5 to 6 days, a perceived as bad body odor is significantly reduced and surprisingly often even permanently eliminated (“application success").
• the present invention also relates to tyrothricin for use in the treatment and / or prophylaxis of body odor in humans.
• Tyrothricin is hereby preferably part of a composition according to the invention, as described below.
• the present invention also relates to a method for the therapeutic or non-therapeutic, preferably cosmetic, treatment and / or prophylaxis of body odor in humans, wherein tyrothricin or a composition containing tyrothricin, preferably a composition according to the invention, as described below, locally, superficial on the, preferably wound-free, skin and / or, preferably wound-free, mucosa is applied.
• tyrothricin or a composition containing tyrothricin, preferably a composition according to the invention as described below
• the aforementioned application to the, preferably wound-free, skin preferably takes place in a therapeutically or non-therapeutically, preferably cosmetically, effective dose.
• a method according to the invention and / or a use according to the invention and / or an application according to the invention of tyrothricin and / or a composition containing tyrothricin, preferably according to the invention (preferably as described below), in each case for treatment and / or Prophylaxis of body odor in humans, is basically suitable for daily use, preferably for once or twice daily use, even over long periods.
• tyrothricin and / or a composition containing tyrothricin preferably as described below
• tyrothricin and / or a composition containing tyrothricin preferably according to the invention (preferably as described below) for a treatment period or a first treatment period, preferably in the range of 1 to 7 days, preferably in the range of 2 to 7 days, more preferably in the range of 3 to 7 days and most preferably in the range of 5 to 6 days, at least once a day, preferably twice a day, more preferably twice a day, once each morning and evening, locally, superficially applied, preferably the Treatment period is not repeated more often than every 7 days, more preferably no more than every 14 days, and / or preferably the application to the wound
• tyrothricin and / or a composition containing tyrothricin preferably according to the invention, after a first treatment period (as above defined or as defined above as preferred), for a second or further treatment period ("relapse prophylaxis"), preferably in the range of 1 to 4 days, preferably in the range of 2 to 3 days, at least once a day locally, superficially applied, preferably twice a day, more preferably twice a day, once in the morning and in the evening, wherein preferably the second or further treatment period is not repeated more frequently than every 30 days, more preferably not more frequently than every 21 days, most preferably not more more frequently than every 14 days, calculated from the end of the first or previous treatment period, and / or preferably with application to the wound-free skin and / or
• tyrothricin or a composition containing tyrothricin may be administered locally, superficially in conventional administration forms.
• creams, gels, lotions, powders, powders, powder sprays, roll-on preparations, ointments, foams, sprays, sticks and tinctures which are known per se are suitable for application, preferably to the wound-free skin surface.
• mucous membrane are - in the case of the oral mucosa - for example, known candies, lozenges, lozenges, sublingual tablets, Buccaltabletten, dragees or rinsing or gargling solutions.
• mucous membrane in the case of the vaginal mucosa, for example, known creams, gels, lotions, powders, powder sprays, ointments, foams, sprays, tinctures, rinsing solutions or suppositories are suitable.
• the present invention also relates to a therapeutic, preferably pharmaceutical, or non-therapeutic, preferably cosmetic, composition containing tyrothricin, preferably in an antimicrobially effective amount, and at least one keratolytic, preferably in a keratolytically effective amount, preferably for use in the treatment and / or prophylaxis of body odor in humans.
• Preferred compositions according to the invention are odorless.
• many prior art compositions for the treatment and / or prophylaxis of body odor in humans - such as deodorants or anti-perspirants - have a more or less strong odor.
• composition of the invention is suitable for use in the context of the inventive use of tyrothricin or in the context of the inventive aspect "tyrothricin for use in the treatment and / or prophylaxis of body odor in humans" provided therefor, preferably in the treatment and / or prophylaxis of Body odor in humans, the body odor emanating from the skin surface, preferably from the foot and / or the armpit and / or an intertriginous area.
• the uppermost skin layer preferably the uppermost layer of the epidermis (stratum corneum)
• the keratolytic agent so that, on the one hand, fewer or no more skin residues are present for decomposition by microorganisms, such as Bacteria are available and that, on the other hand, the local action of the active substance tyrothricin on the skin surface or the skin area, from which emanates a perceived as unpleasant body odor, facilitates, favors and / or only made possible.
• the keratolytic agent is preferably selected from the group consisting of ⁇ -hydroxy acids, preferably glycolic acid, mandelic acid and / or lactic acid; acitretin; adapalene; allantoin; alumina; azelaic acid; benzoyl peroxide; Urea; isotretinoin; Monochloroacetic acid; motretinide; retinoids; salicylic acid; Shale oils; selenium disulphide; tazarotene; Tar; Tretinoin and mixtures of the above keratolytics.
• Urea is particularly preferred according to the invention as a keratolytic.
• tyrothricin is present in an amount ranging from 0.01 to 0.5% by weight, preferably in a range from 0.05 to 0.2% by weight. %, based on the total mass of the composition, and / or (preferably "and") wherein urea in an amount in a range of 0.5 to 20.0 wt .-%, preferably in a range of 1, 0 to 15.0 wt .-%, particularly preferably in a range of 3.0 to 12.0 wt .-%, based on the total mass of the composition.
• compositions according to the invention Preference is given to a composition according to the invention or one or more of the preferred compositions given below, furthermore containing one or more polyethylene glycols (hereinafter also abbreviated to "PEG") and / or propylene glycol odor-free (odor-free) such a composition is particularly preferred
• PEG polyethylene glycols
• Preferred polyethylene glycols for use in inventive or preferred compositions according to the invention are selected from the group of polyethylene glycols having an average molecular weight in the range of 200 to 12,000, preferably in the range of 200 to 8000, most preferably in the range from 200 to 6000, preferably determined by means of size exclusion chromatography.
• preferred types of polyethylene glycols are selected from the group consisting of PEG 300, PEG 400, PEG 600, PEG 1500, PEG 2000, PEG 3000 and PEG 4000, where the numbers indicate the average molecular weights in a manner conventional to those skilled in the art.
• a polyethylene glycol type of a certain average molecular weight eg "PEG 300" or “PEG 1500”
• PEG 300 or PEG 1500 can be used alone or it is advantageously possible to use mixtures of two or more types of polyethylene glycol each having a specific average molecular weight, eg "PEG 300 "in mixture with” PEG 1500 ".
• polyethylene glycol grades of suitable average molecular weights or mixtures of two or more types of polyethylene glycols each having a specific average molecular weight compositions of various consistencies or viscosities according to the invention can be prepared and the desired use (such as ointment or as filling for a deodorant).
• propylene glycol (1,2-dihydroxypropane) comprises all isomers of this compound, both the optically active compounds ((R) - and (S) - 1, 2-dihydroxypropane) and mixtures thereof, in particular the racemate.
• compositions according to the invention or above or below as being preferably indicated which comprises polyethylene glycols and / or propylene glycol (as described above individually or as mixtures of several polyethylene glycol types with one another and / or with propylene glycol) in a total amount (polythylene glycol (s) plus propylene glycol) in the range of 15 to 90 wt .-%, preferably in the range of 30 to 90 wt .-%, particularly preferably in the range of 40 to 90 wt .-%, based on. the total mass of the composition.
• compositions according to the invention containing one or more polyethylene glycols and / or propylene glycol have a number of advantages:
• compositions according to the invention which contain a total amount of 15% by weight or more, based on the total weight (or the total mass) of the composition, of one or more polyethylene glycols and / or propylene glycol have an antibacterial or preservative effect so that additional preservatives are generally unnecessary or need not be added to the compositions.
• Compositions according to the invention of oily consistency ("oils") are preferably filled and stored in brown glass bottles to increase stability.
• Compositions according to the invention in the form of an ointment are preferably filled and stored in a coated, preferably PVC-free, aluminum tube.
• polyethylene glycols and propylene glycol have a very good compatibility. It has also been shown in own experiments that a possibly to be feared (possibly slowly occurring) decomposition of urea and thereby increasing pH levels in the composition, which could lead to adverse effects on the active ingredient tyrothricin, in compositions of the invention which polyethylene glycols and / or Propylene glycol contained, did not occur or were not observed. On the contrary, such aforementioned preferred compositions of the present invention were stable over extended periods of time.
• Another advantage of the use of propylene glycol in the context of the present invention is a penetration-promoting effect, whereby the advantageous keratolytic effect of urea described above can be supported or enhanced.
• composition according to the invention which contains, in addition to tyrothricin and urea, only polyethylene glycols and / or propylene glycol.
• composition according to the invention which is preferred or given above or below as being preferred, which additionally contains a wetting agent, preferably selected from the group consisting of polydimethylsiloxanes, polyethylene oxides, polysorbates and mixtures thereof.
• a wetting agent preferably selected from the group consisting of polydimethylsiloxanes, polyethylene oxides, polysorbates and mixtures thereof.
• Particularly preferred as wetting agent in this context is polydimethylsiloxane (PDMS), also known by the name Dimeticon (INN), CAS RN 9006-65-9.
• composition according to the invention or above or below as preferred which additionally contains a skin-compatible pH regulator, preferably a buffer system, more preferably a buffer system, which is used for adjusting or buffering a pH in the range from 7.1 to 8.5, preferably in the range of 7.5 to 8.0, for example per se known phosphate buffer, tris (hydroxymethyl) aminomethane buffer (also called trometamol) or borate buffer.
• a composition according to the invention which contains urea as keratolytic preferably has a pH which is not higher than 8.0 and is preferably stabilized by a buffer system.
• composition according to the invention which additionally contains a denaturing agent, preferably a denatonium derivative, particularly preferably selected from the group consisting of denatonium benzoate and denatonium saccharinate.
• a denaturing agent preferably a denatonium derivative, particularly preferably selected from the group consisting of denatonium benzoate and denatonium saccharinate.
• composition according to the invention or above or below is preferably a topical composition, particularly preferably in a form selected from the group consisting of cream, gel, lotion, powder, powder, powder spray, oil, roll-on preparation, ointment, Foam, spray, stick and tincture, more preferably from the group consisting of cream, gel, lotion, powder, powder, powder spray, oil, roll-on preparation, ointment and spray.
• a topical composition according to the invention is preferably in a form selected from the group consisting of cream, powder, powder, powder spray, ointment and spray.
• Particularly preferred in this connection is a topical composition according to the invention in the form of a cream, an ointment or a powder.
• a topical composition of the invention in a form selected from the group consisting of gel, lotion, powder, oil, roll -one preparation, foam, spray and pen.
• a topical composition according to the invention in the form of a cream, an ointment, an oil or a roll-on preparation.
• a topical composition in a form selected from the group consisting of cream, gel, lotion, powder, powder, powder spray, ointment, foam, spray, stick and tincture.
• a topical composition in the form of a cream, gel, ointment, foam or spray.
• the invention also relates to the use of a composition according to the invention or a preferred composition according to the invention and / or of a topical composition according to the invention or of a topical composition according to the invention, each for the treatment and / or prophylaxis of body odor in humans, preferably in the treatment and / or prophylaxis of Body odor in humans, wherein the body odor emanates from the skin surface, preferably from the foot and / or the armpit and / or an intertriginous area.
• the invention likewise relates to a composition according to the invention or to a preferred composition given above and / or to a topical composition according to the invention or to a preferred topical composition according to the invention, in each case for use in the treatment and / or prophylaxis of body odor in humans
• composition according to the invention or one of the above preferably preferred compositions containing tyrothricin and a keratolytic agent, preferably urea, is preferred on the skin surface, preferably at sites where the skin or cornea is poorly aerated and / or on Where the skin or cornea is swollen and / or completely or partially macerated, has lesions (especially in cases of "keratoma sulcatum", “pitted keratolysis” or “plantar pitting", see above) and / or symptoms of bromohidrosis,
• the present invention also relates to a kit containing the spatially separated components a) a composition suitable for topical administration comprising tyrothris in an antimicrobially effective amount and b) at least one composition suitable for topical administration, containing in each case at least one keratolytic agent in a keratolytically effective amount.
• composition suitable for topical administration is preferably selected from the group consisting of cream, gel, lotion, powder, powder, powder spray, roll-on preparation, ointment, foam, spray, stick and tincture, particularly preferably from the group from cream, gel, lotion, powder, powder, powder spray, roll-on preparation, ointment and spray
• composition suitable for topical administration also encompasses premixes and precursors which are in front of a proper Application or application must first be converted into a ready-to-use form or in a ready-to-use composition.
• the invention also relates to a kit as indicated above, for use in the treatment and / or prophylaxis of body odor in humans and / or the use of a above-mentioned inventive kit for the treatment and / or prophylaxis of body odor in humans.
• the invention also relates to a kit for the above-mentioned application or use in the treatment and / or prophylaxis of body odor in humans, wherein the application comprises the preferably alternating application of the components a) and b) to the wound-free skin over a treatment time - Spaces, which is sufficient to reduce the associated with perspiration body odor at least for a success period, preferably at least for a success period to eliminate.
• the terms treatment period or success period preferably have the same meaning as stated above (in connection with the description of an application success).
• the present invention further relates to an article of footwear, preferably a shoe insert, insole, sock, sock or footlet containing an antimicrobially effective amount of tyrothricin.
• tyrothricin no other antibacterial (antibiotic) and / or antiseptic agent is preferably used in all aspects of the invention (use, application, composition, use of the composition, kit, use of the kit), but a keratolytic agent which can be used according to the invention, preferably urea, in the context of the present invention should not be regarded as preferably to be avoided antibacterial and / or antiseptic agent.
• a keratolytic agent which can be used according to the invention, preferably urea, in the context of the present invention should not be regarded as preferably to be avoided antibacterial and / or antiseptic agent.
• the use of tyrothricin as the sole antibacterial and / or antiseptic agent has, inter alia, the advantage that a treatment according to the invention of body odor brings with it only a very low risk for the development or emergence of resistant germs.
• Example 1 Preparation of a composition according to the invention (ointment) containing
• Table 1 Composition of an ointment according to the invention
• composition according to the invention prepared in Example 1 is particularly suitable for application to the skin of the foot affected by body odor, in particular the soles of the feet.
• Example 2 Preparation of a Composition According to the Invention (Oil) Containing Tyhrothricin and a Keratolytic
• composition according to the invention (oil) prepared in Example 2 is suitable, for example, for filling a deodorant roller or for direct application to skin-affected areas of the skin, for example on the soles of the feet or in the axillary or intertriginous areas.
• Example 3 Preparation of a Composition According to the Invention (Oil) Containing Tyrothricin and a Keratolytic
• composition according to the invention (oil) prepared in Example 3 is suitable, for example, for filling a deodorant roller or for direct application to skin-affected areas of the skin, for example on the soles of the feet or in the axillary or intertriginous areas.
• Example 4 Test series for verifying the efficacy of tyrothricin in the treatment of body odor on subjects
• test series was carried out with 22 volunteers ("test persons", 14 males, 8 females) who at the beginning of the test series suffered from unpleasant body odor emanating from the skin surface of the foot ("foot odor").
• Table 4 Classification of the test persons by strength of the foot odor
• test ointment containing 0.1% tyrothricin and corresponding to the composition of Example 1
• treatment period a period of 6 days
• Subjects should not change their personal care habits during the duration of the test series and for a follow-up period after the end of the test series (30 days), but any individual or foot odor treatment (other than treatment according to the invention) for the duration of the test series and / or the connection period.
• any individual or foot odor treatment (other than treatment according to the invention) for the duration of the test series and / or the connection period.
• the wearing of footwear was allowed, but barefoot walking as possible to refrain.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Tropical Medicine & Parasitology (AREA)
• Biotechnology (AREA)
• Engineering & Computer Science (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Socks And Pantyhose (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Saccharide Compounds (AREA)

Priority Applications (18)

Applications Claiming Priority (2)

Publications (1)

Family

ID=62904430

Family Applications (1)

Country Status (21)

Cited By (1)

Families Citing this family (1)

Citations (9)

Family Cites Families (5)

• 2018
  • 2018-07-03 SM SM20220149T patent/SMT202200149T1/it unknown
  • 2018-07-03 RU RU2020107394A patent/RU2020107394A/ru unknown
  • 2018-07-03 SI SI201830530T patent/SI3654932T1/sl unknown
  • 2018-07-03 PT PT187401401T patent/PT3654932T/pt unknown
  • 2018-07-03 WO PCT/EP2018/067991 patent/WO2019015955A1/de not_active Ceased
  • 2018-07-03 AU AU2018302367A patent/AU2018302367B2/en active Active
  • 2018-07-03 HU HUE18740140A patent/HUE057646T2/hu unknown
  • 2018-07-03 ES ES18740140T patent/ES2904900T3/es active Active
  • 2018-07-03 MX MX2020000681A patent/MX2020000681A/es unknown
  • 2018-07-03 CN CN201880057627.7A patent/CN111093611B/zh active Active
  • 2018-07-03 US US16/632,700 patent/US20200139164A1/en not_active Abandoned
  • 2018-07-03 DK DK18740140.1T patent/DK3654932T3/da active
  • 2018-07-03 JP JP2020524673A patent/JP7292272B2/ja active Active
  • 2018-07-03 EP EP18740140.1A patent/EP3654932B1/de active Active
  • 2018-07-03 CA CA3070246A patent/CA3070246A1/en active Pending
  • 2018-07-03 LT LTEPPCT/EP2018/067991T patent/LT3654932T/lt unknown
  • 2018-07-03 KR KR1020207004989A patent/KR20200031673A/ko not_active Ceased
  • 2018-07-03 PL PL18740140T patent/PL3654932T3/pl unknown
  • 2018-07-03 HR HRP20220034TT patent/HRP20220034T1/hr unknown
  • 2018-07-03 RS RS20220029A patent/RS62825B1/sr unknown
• 2022
  • 2022-01-10 CY CY20221100024T patent/CY1124904T1/el unknown

Patent Citations (9)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events